BioTelemetry Inc. (BEAT)

34.50
NASDAQ : Health Technology
Prev Close 33.90
Day Low/High 33.60 / 34.65
52 Wk Low/High 23.30 / 39.20
Avg Volume 370.70K
Exchange NASDAQ
Shares Outstanding 32.73M
Market Cap 1.11B
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Short Interest In BioTelemetry Makes 57.2% Move

Short Interest In BioTelemetry Makes 57.2% Move

The most recent short interest data has been released for the 12/29/2017 settlement date, which shows a 1,318,658 share increase in total short interest for BioTelemetry Inc , to 3,622,167, an increase of 57.25% since 12/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

First Week of BEAT August 2018 Options Trading

First Week of BEAT August 2018 Options Trading

Investors in BioTelemetry Inc saw new options begin trading this week, for the August 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

BioTelemetry Breaks Above 200-Day Moving Average - Bullish for BEAT

BioTelemetry Breaks Above 200-Day Moving Average - Bullish for BEAT

In trading on Monday, shares of BioTelemetry Inc crossed above their 200 day moving average of $30.75, changing hands as high as $30.85 per share. BioTelemetry Inc shares are currently trading up about 2.5% on the day.

Interesting BEAT Put And Call Options For January 2018

Interesting BEAT Put And Call Options For January 2018

Investors in BioTelemetry Inc saw new options become available this week, for the January 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BEAT options chain for the new January 2018 contracts and identified one put and one call contract of particular interest.

Oversold Conditions For BioTelemetry (BEAT)

Oversold Conditions For BioTelemetry (BEAT)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

BioTelemetry Research And AMRA Raise The Standard For Medical Imaging In NASH/NAFLD Clinical Trials

BioTelemetry Research And AMRA Raise The Standard For Medical Imaging In NASH/NAFLD Clinical Trials

First to Market Alliance Increases Precision and Specificity while Reducing Cost

BioTelemetry is Now Oversold (BEAT)

BioTelemetry is Now Oversold (BEAT)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

BEAT Makes Notable Cross Below Critical Moving Average

BEAT Makes Notable Cross Below Critical Moving Average

In trading on Tuesday, shares of BioTelemetry Inc crossed below their 200 day moving average of $30.11, changing hands as low as $29.85 per share. BioTelemetry Inc shares are currently trading off about 1.3% on the day.

Delta Air Lines, BioTelemetry, TransUnion: 'Mad Money' Lightning Round

Delta Air Lines, BioTelemetry, TransUnion: 'Mad Money' Lightning Round

Jim Cramer is bullish on Delta Air Lines, BioTelemetry, TransUnion, Amgen and Littelfuse.

Are Stocks Cheaper Than We Think?: Cramer's 'Mad Money' Recap (Tues 10/17/17)

Are Stocks Cheaper Than We Think?: Cramer's 'Mad Money' Recap (Tues 10/17/17)

Jim Cramer says there's a case to be made for underpricing, even in this market.

BioTelemetry: Cramer's Top Takeaways

BioTelemetry: Cramer's Top Takeaways

Joe Capper, president and CEO of BioTelemetry, tells Jim Cramer that the connected health market is relatively new and no one really knows just how big it could be.

Beware This Bull Stampede: Cramer's 'Mad Money' Recap (Tuesday 10/3/17)

Beware This Bull Stampede: Cramer's 'Mad Money' Recap (Tuesday 10/3/17)

Jim Cramer says that with the exception of the department stores and the oils, a case can be made for almost anything in this market.

Rocket Stocks Look Better on Re-Entry: Cramer's 'Mad Money' Recap (Mon 9/25/17)

Rocket Stocks Look Better on Re-Entry: Cramer's 'Mad Money' Recap (Mon 9/25/17)

Jim Cramer looks at the high-flying FANG stocks, and says he likes these companies best when their prices return to earth.

Siding With the Bulls on BioTelemetry: Cramer's Top Takeaways

Siding With the Bulls on BioTelemetry: Cramer's Top Takeaways

Cramer takes a closer look at heart-monitor company BioTelemetry.

Short Interest Falls 33.7% For BEAT

Short Interest Falls 33.7% For BEAT

The most recent short interest data has been released for the 08/15/2017 settlement date, which shows a 850,459 share decrease in total short interest for BioTelemetry Inc , to 1,674,666, a decrease of 33.68% since 07/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

BioTelemetry Reaches Analyst Target Price

BioTelemetry Reaches Analyst Target Price

In recent trading, shares of BioTelemetry Inc have crossed above the average analyst 12-month target price of $36.00, changing hands for $36.35/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Saber-Rattling Sparks Selling

VIX climbs while gold and bonds catch a bid.

BEAT Crosses Above Average Analyst Target

BEAT Crosses Above Average Analyst Target

In recent trading, shares of BioTelemetry Inc have crossed above the average analyst 12-month target price of $33.00, changing hands for $34.40/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

BioTelemetry, Inc. Completes LifeWatch AG Acquisition

BioTelemetry, Inc. Completes LifeWatch AG Acquisition

Deal Solidifies BioTelemetry's Leadership Position in Remote Cardiac Monitoring

BEAT Crosses Above Average Analyst Target

In recent trading, shares of BioTelemetry Inc have crossed above the average analyst 12-month target price of $28.67, changing hands for $29.65/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

TheStreet Quant Rating: C (Hold)